Critically Hematological Ill Patients Antimicrobial Stewardship (C.H.I.P.S) in intensive care unit: a global cross-sectional survey—an international research project within the Nine-i investigators network
Critically Hematological Ill Patients Antimicrobial Stewardship (C.H.I.P.S) in intensive care unit: a global cross-sectional survey—an international research project within the Nine-i investigators network
复制标题
重症监护病房中的重症血液病患者抗菌药物管理 (C.H.I.P.S)：一项全球横断面调查 — Nine-i 研究人员网络内的一项国际研究项目
DOI：
10.21037/jeccm.2019.04.01
复制
发表时间：
2019
期刊：
影响因子：
--
通讯作者：
J. Rello
中科院分区：
文献类型：
--
作者：
C. Sarda;A. Tabah;D. Mokart;E. Alp;K. Arvaniti;M. Akova;J. Rello
工作背景：危重血液病患者抗菌药物管理（C. H. I. P. S）是一项全球横断面调查，将描述入住重症监护室（ICU）的血液病患者中最具临床相关性的细菌和抗菌药物耐药模式。与此同时，将提供全球感染控制和治疗专家挑战。方法：将使用电子平台（SurveyMonkey ®）进行全球调查。该调查将汇编全球ICU收治的血液病患者中抗生素耐药细菌感染当前治疗的关键方面的数据。对调查问题的所有答复将以汇总统计和报告比例的形式提供。将通过卡方检验或Fisher精确检验进行统计分析，以评价潜在的相关性。
讨论内容：在不久的将来，应努力制定针对危重血液病患者的建议和抗菌药物管理（AMS）计划。预防策略、抗菌治疗的类型和时机、降阶梯（ADE）方法必须针对这些患者量身定制。
Background: Critically Hematological Ill Patients Antimicrobial Stewardship (C.H.I.P.S) is a global cross-sectional survey will describe the most clinical relevant bacteria and antimicrobial pattern of resistance among hematological patients admitted to intensive care units (ICU). At the same time, a global expert challenges on infection control and treatment will be provided. Methods: A global survey will be performed using an electronic platform (SurveyMonkey ® ). The survey will compile data on key aspects of the current treatment of antimicrobial-resistant bacteria infections among hematological patients admitted in ICU worldwide. All responses to survey questions will be presented as summary statistics and reporting proportions. Statistical analysis by Chi-square test or Fisher’s exact test will be performed to evaluate potential associations.
Discussion: Efforts on the development of recommendations and antimicrobial stewardship (AMS) programs focused on critical hematological patients should be directed in the near future. Prevention strategies, type and, timing of antimicrobial therapy, de-escalation (ADE) approach have to be tailored to these patients.